Computational assessment of targeting angiotensin-converting enzyme for hypertension management: A structure-based virtual screening approach
Abstract
Background: Hypertension is a growing public health concern globally. The angiotensin-converting enzyme (ACE) is an enzyme that cleaves the carboxy-terminal His-Leu dipeptide from angiotensin I, yielding the potent vasopressor octapeptide, angiotensin II. ACE inhibitors are a primary treatment option for hypertension, heart failure, and myocardial infarction. However, the use of synthetic ACE inhibitors has been linked to a number of side effects. Therefore, the development of novel and safe ACE inhibitors is a need of time.
Methods: This study used a computational screening of a library of known compounds with anti-inflammatory activities against the active site of ACE using the PyRx-Python 0.8 tool to find more potent ACE inhibitors with less or no side effects. The physicochemical properties of the anti-inflammatory compounds were obtained from the Life Chemicals website.
Result: The five hits, specifically F3398-2114, F0193-0245, F0163-0089, F0193-0237, and F0302-0060, exhibited notable interactions within the ACE binding pocket and demonstrated greater binding energy compared to the control compound, Lisinopril. All of these compounds displayed favorable physicochemical characteristics and aligned to Lipinski's rule.
Conclusion: The compounds F3398-2114, F0193-0245, F0163-0089, F0193-0237, and F0302-0060 have the potential to be used as ACE inhibitors; however, further experimental validation is required to optimize them as ACE inhibitors.
Keywords: Hypertension; Angiotensin-converting enzyme; Heart failure; Lipinski's rule
Full Text:
PDFReferences
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews Nephrology, (2020); 16(4): 223-237.
Wajngarten M, Silva GS. Hypertension and Stroke: Update on Treatment. European Cardiology Review, (2019); 14(2): 111-115.
Buonacera A, Stancanelli B, Malatino L. Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice. Current Vascular Pharmacology, (2019); 17(1): 72-84.
Shen B, El-Dahr SS. Cross-talk of the renin-angiotensin and kallikrein-kinin systems. Biological Chemistry, (2006); 387(2): 145-150.
Ahmad H, Khan H, Haque S, Ahmad S, Srivastava N, et al. Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension. Journal of the Renin-Angiotensin-Aldosterone System, (2023); 2023: 7890188.
Zheng W, Tian E, Liu Z, Zhou C, Yang P, et al. Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Frontiers in Pharmacology, (2022); 13: 968104.
Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Annals of Pharmacotherapy, (1996); 30(1): 55-61.
Horl WH. [ACE inhibitors and the kidney]. Wien Med Wochenschr, (1996); 146(16): 450-453.
McNeely W, Wiseman LR. Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs, (1998); 56(1): 91-114.
Talevi A. Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects. Methods in Molecular Biology, (2024); 2714: 1-20.
Yu W, MacKerell AD, Jr. Computer-Aided Drug Design Methods. Methods in Molecular Biology, (2017); 1520: 85-106.
Sliwoski G, Kothiwale S, Meiler J, Lowe EW, Jr. Computational methods in drug discovery. Pharmacological Reviews, (2014); 66(1): 334-395.
Natesh R, Schwager SL, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature, (2003); 421(6922): 551-554.
Warner NJ, Rush JE. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs, (1988); 35: 89-97.
Shoichet BK. Virtual screening of chemical libraries. Nature, (2004); 432(7019): 862-865.
Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. Journal of Pharmaceutical Sciences, (2013); 16(5): 821-847.
Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacological Research, (2018); 129: 95-99.
Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, et al. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension, (2022); 79(1): 293-301.
Kumbhare RM, Kosurkar UB, Bagul PK, Kanwal A, Appalanaidu K, et al. Synthesis and evaluation of novel triazoles and mannich bases functionalized 1,4-dihydropyridine as angiotensin converting enzyme (ACE) inhibitors. Bioorganic & Medicinal Chemistry, (2014); 22(21): 5824-5830.
Jung IH, Kim SE, Lee YG, Kim DH, Kim H, et al. Antihypertensive Effect of Ethanolic Extract from Acanthopanax sessiliflorus Fruits and Quality Control of Active Compounds. Oxidative Medicine and Cellular Longevity, (2018); 2018: 5158243.
Shaikh S, Aaqil H, Rizvi SM, Shakil S, Abuzenadah AM, et al. Comparative Inhibition Study of Compounds Identified in the Methanolic Extract of Apamarga Kshara Against Trichomonas vaginalis Carbamate Kinase (TvCK): An Enzoinformatics Approach. Interdisciplinary Sciences: Computational Life Sciences, (2016); 8(4): 357-365.
Alqahtani LS, Alkathiri AS, Alzahrani A, Alghamdi RM, Alamri WA et al. Structure-Based Virtual Screening of Antiviral Compounds Targeting the Norovirus RdRp Protein. Advancements in Life Sciences, (2024); 11(2): 670-681.
Sayed Murad HA, M MR, Alqahtani SM, B SR, Alghamdi S, et al. Molecular docking analysis of AGTR1 antagonists. Bioinformation, (2023); 19(3): 284-289.
Abdulrahman A, Mohammad Azhar K, Asif Hussain A, Ali Abdullah A, Marui IS, et al. Molecular docking analysis of MCL-1 inhibitors for breast cancer management. Bioinformation, (2023); 19(6): 707-712.
Tarique M, Ahmad S, Malik A, Ahmad I, Saeed M, et al. Correction to: Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and Other Coronaviruses: A Genome-wide Comparative Annotation and Analysis. Molecular and Cellular Biochemistry, (2022); 477(2): 645.
DOI: http://dx.doi.org/10.62940/als.v11i4.3020
Refbacks
- There are currently no refbacks.